Folkesson H G
IDrugs : the investigational drugs journal
Fosfructose is a cytoprotective natural sugar phosphate under development by Questcor (formerly Cypros) for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions. It is in phase III trials for sickle cell anemia  and is in phase II/III trials for cardiovascular ischemia resulting from bypass surgery . The company has also commenced preclinical trials of fosfructose for asthma . In September 1999, the FDA granted fosfructose Fast Track designation for the treatment of the acute complications associated with coronary artery bypass graft surgery .
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Folkesson H G, “Fosfructose (Questcor).,” NEOMED Bibliography Database, accessed December 6, 2023, https://neomed.omeka.net/items/show/5402.